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Abstract In the last decades, several gene expression-
based predictors of clinical behavior were developed for
breast cancer. A common feature of these is the use of
multiple genes to predict hormone receptor status and the
probability of tumor recurrence, survival or response to
chemotherapy. We developed an online analysis tool to
compute ER and HER2 status, Oncotype DX 21-gene
recurrence score and an independent recurrence risk clas-
sification using gene expression data obtained by interro-
gation of Affymetrix microarray profiles. We implemented
rigorous quality control algorithms to promptly exclude
any biases related to sample processing, hybridization and
scanning. After uploading the raw microarray data, the
system performs the complete evaluation automatically and
provides a report summarizing the results. The system is
accessible online at http://www.recurrenceonline.com. We
validated the system using data from 2,472 publicly
available microarrays. The validation of the prediction of
the 21-gene recurrence score was significant in lymph node
negative patients (Cox-Mantel, P = 5.6E-16, HR = 0.4,
CI = 0.32–0.5). A correct classification was obtained for
88.5% of ER- and 90.5% of ER ? tumors (n = 1,894).
The prediction of recurrence risk in all patients by using the
mean of the independent six strongest genes (P \ 1E-16,
HR = 2.9, CI = 2.5–3.3), of the four strongest genes in
lymph node negative ER positive patients (P \ 1E-16,
HR = 2.8, CI = 2.2–3.5) and of the three genes in lymph
node positive patients (P = 3.2E-9, HR = 2.5, CI =
1.8–3.4) was highly significant. In summary, we integrated
available knowledge in one platform to validate currently
used predictors and to provide a global tool for the online
determination of different prognostic parameters simulta-
neously using genome-wide microarrays.
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Introduction
Recently available multigenic prognostic biomarkers
promise to provide a prediction efficiency superior to
monogenic tests, enabling better patient tailored therapy in
the treatment of breast cancer. In essence, development is
carried out on two major platforms, including RT-PCR-
based Oncotype DX [1], Theros Breast Cancer Index [2],
Breast bioclassifier [3], Celera metastatic score [4], 8-gene
score [5] and microarray-based Mammaprint [6], Map-
Quant Dx [7], BLN assay [8], Invasive Gene Signature [9]
and Wound Response Indicator [10]. In addition, the FISH-
based eXagen test [11] and the IHC-based Mammostrat
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[12] are available (see Table 1). Most of these datasets
were summarized and evaluated in our recent meta-anal-
ysis [13].
Of the above mentioned tests, the Oncotype DX assay is
by far the most widely used with over 135,000 tests per-
formed already (Genomic Health Annual report, 2009).
Here, FFPE samples are sent to a single laboratory, where
the isolation of RNA and analysis are performed. Twenty-
one genes are quantified in the test to predict distant
recurrence in breast cancer patients with lymph-node
negative, estrogen-receptor (ER) positive tumors. Patients
are classified into high/intermediate/low risk of recurrence
based on the recurrence score, which is computed using an
precisely defined mathematical formula [1]. The assay not
only provides prediction of relapse-free survival, but also
predicts the risk of locoregional recurrence [14]. It might
also support the treatment decision whether a patient
should receive adjuvant chemotherapy [15]. The benefit of
adjuvant chemotherapy over and above endocrine therapy
differs greatly in the assay-determined risk categories [16].
The effect of Oncotype Dx on physicians’ decision-making
for systemic adjuvant therapy ranged from 25% [17] to
44% [18]. The actual cost of the assay itself seems to be
well justified by saving the cost of unnecessary chemo-
therapy [19]. However, significant weaknesses of the test
are the lack of any independent quality control and the slow
processing requiring several weeks.
Determining estrogen receptor status accurately is
essential to identify patients eligible for endocrine therapy
in breast cancer. Another receptor of significant clinical
importance is HER2 (ERBB2), which is over-expressed in
over 25% of invasive ductal breast cancers [20]. The ele-
vated levels of HER2 are associated with increased pro-
liferation and poor prognosis [21]. Immunhistochemistry
based HER2 positive patients are eligible for first-line
trastuzumab treatment in combination with chemotherapy
[22] and for monotherapy in patients who progressed after
chemotherapy [23]. Trastuzumab treatment results in
increased response rate and longer survival [22].
A genome-wide Affymetrix microarray measures over
22,000 genes including the hormone receptors and those
genes used in different multigenic breast cancer classifi-
cations. Here, we report the development of an online
analysis tool which is capable of computing ER and HER2
status and the risk of recurrence using gene expression data
obtained by interrogating Affymetrix HGU133A and
HGU133Aplus2 microarrays. Furthermore, we imple-
mented rigorous quality control algorithms to promptly
exclude any biases related to sample processing, hybrid-
ization and scanning. We performed a validation of the
system in 2,472 breast cancer specimens obtained from
microarray datasets published in GEO.
Methods
Server set-up
All computations on the raw microarray data are performed
in real time (Fig. 1). Recurrence online is set up using a
Table 1 Summary of multigenic tests developed for breast cancer
Name Company Available No of
genes
Sample Technique Diagnostic aim
Oncotype Dx Genomic Health EU, USA 21 FFP Q-RT-PCR Prognosis, recurrence after
tamoxifen therapy
Theros Breast Cancer Index Biotheranostics USA 2(5) FFP Q-RT-PCR Prognosis, recurrence after
endocrine therapy
Breast Bioclassifier ARUP USA 55 FFP RT-PCR Prognosis
Celera Metastatic Score Applera – 14 FFP RT-PCR Prognosis, recurrence after
tamoxifen therapy
eXagen eXagen diagnostics – 3 FFP FISH Prognosis
Mammostrat Applied genomics USA 5 IHC Prognosis
ProEX
TM
Br TriPath – 5 IHC Prognosis
MammaPrint Agendia EU, USA 70 F/F Microarray Prognosis in patients over
61 years
MapQuant Dx Ipsoggen EU 97 F/F Microarray Prognosis
Breast Lymph Node (BLN) Assay GeneSearch Veridex UK 76 F/F Microarray Intraoperative metastasis
identification
Invasive Gene Signature – – 186 F/F Microarray Prognosis
Wound Response Indicator – – 512 F/F Microarray Prognosis
F/F fresh/frozen, FFP formalin-fixed paraffin-embedded, IHC immunohistochemistry, FISH fish fluorescent in situ hybridization
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central server accessible via the internet. The central server
runs an Apache webserver and a (D)COM server which
provides statistical computations in R. After a secure
upload of the .CEL file, data is loaded into the R statistical
environment, where the calculations are performed. The
package ‘‘affy’’ is used for normalization. For the valida-
tion, the background database is handled by a MySQL
server, which integrates gene expression and clinical data
simultaneously. The homepage was constructed using a
modular online system built in the freely available drupal (
www.drupal.org) environment. The user receives feedback
from the webpage.
We focused on the two most widely used human
microarray platforms, the Affymetrix HGU133A (GEO
platform ID: GPL96) and the Affymetrix HGU133plus2
(GEO platform ID: GPL570). The final output of a
hybridization of an Affymetrix microarray is the acquisi-
tion of a .CEL file, which contains all the raw results of the
microarray. The implemented various metrics of our tool
rely on these raw .CEL files. The input window of recur-
renceonline.com is presented in Fig. 2a.
Array quality control
Heber and Sick [24] suggested eight quality metrics as a
basic quality assessment for Affymetrix microarrays. First,
we have implemented their methods and tested them on an
extended version of our previously published database [25].
The distribution of the arrays was assessed and outliers were
identified as those having a parameter value outside of the
range of 95% of samples. Then, the ‘‘Array quality control’’
parameter implemented in www.recurrenceonline.com was
set to give a warning in cases in which the thresholds pub-
lished by Heber et al. are surpassed or outliers are detected as
compared to our meta-analysis. The cutoff values are sum-
marized in Table 2.
Computation of the recurrence score
After the quality control the raw Affymetrix .CEL files are
MAS5 normalized in R using the affy Bioconductor library.
MAS5 can be applied to individual chips, making com-
parison to the validation data and future extension of the
Fig. 1 Overview of the server
(a), the eligible tests (b), the
applied analysis corridor in the
online computations (c) and the
implementation of the
validation study (d)
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validation datasets easily feasible. Moreover, MAS5 ranked
among the best normalization methods when compared to
the results of RT-PCR measurements in our recent study
[26]. Then, the differences of the log-transformed expres-
sion of the 16 genes and the housekeeping genes ACTB,
GAPDH, RPLP0, GUS, and TFRC are subtracted from the
‘‘range top’’ (adjustable parameter) to emulate RT-PCR
results. For genes with multiple probe sets represented on
the Affymetrix microarrays the probe set with the highest
average expression or the average expression of available
probe sets can be used (adjustable parameter). Then, the
recurrence score is computed as described by Paik et al.
2004. Finally, samples are classified as being in the high/
intermediate/low group based on their recurrence score.
Assessment of ER and HER2 status
Gong et al. [27] demonstrated the possibility to determine
estrogen receptor and ERBB2 status reliably and reproduc-
ibly using Affymetrix microarrays. We implemented their
Fig. 2 a One-step online
interface is used for input (a).
The analysis results window
b delivers a graphical
assessment of the tested
parameters
Table 2 Parameters implemented in the array quality control metrics
Parameter Recommendation by Heber et al.
for good quality arrays
Range of 95% of arrays in 2,472
breast cancer samples
www.recurrenceonline.com
gives warning if result is
Background Between 10 and 100 normal 40–114 Larger than 100
Scaling factor Smaller than 3 0.3–2.3 Larger than 3
Percent present calls In the range 20–50% 42–58% Smaller than 30%
bioB-, bioC-, bioD- and cre-spikes Always present Not applicable Not present
dap-, lys-, phe-, thr-, tryp-spikes lys \ phe \ thr \ dap Not applicable Not ‘‘lys \ phe \ thr \ dap’’
GAPDH 30 to 50 ratio Close to one 0.28–5 Larger than 4 or smaller than 0.25
Beta-actin 30 to 50 ratio Smaller than 3 0–4.7 Larger than 3
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approach using the suggested cutoff values of 500 (in the
probe set 205225_at) for estrogen receptor and 1,150 (in the
probe set 216836_s_at) for ERBB2 receptor. In addition, for
the ERBB2 receptor the bimodal distribution of the valida-
tion datasets was decomposed into two Gaussian distribu-
tions (which correspond to two specific ERBB2 expression
statuses) as described earlier [28]. Briefly, based on the two
inferred distributions a cohort-specific cut-off value for
ERBB2 using Mahalanobis distance—which minimizes the
estimated false positive rate (FPR) and the false negative
rate (FNR)—was derived. The actual cutoff for ERBB2 is
user selectable: ‘‘bimodal distribution’’ uses 4,800 as cutoff,
while ‘‘immunhistochemistry’’ uses the 1,150 cutoff sug-
gested by Gong et al.
Validation
The validation was performed on microarrays which were
previously published in GEO in following datasets:
GSE1456, GSE2034, GSE2990, GSE3494, GSE4922,
GSE6532, GSE7390, GSE11121, GSE12093, GSE5327,
GSE9195, GSE16391, GSE12276, GSE2603, GSE17705,
and GSE21653. The datasets were generated using
HGU133A or HGU133Aplus2 microarrays which possess
overlapping probe set identifiers and are also used in
www.recurrenceonline.com analyses. The construction of
the database was performed as described earlier [25]. After
classification of the samples as having high/intermediate/
low recurrence scores, the groups were compared using
Kaplan–Meier survival plots in WinSTAT 2007 for Excel
(Robert K. Fitch Software, Germany) and using the ‘‘surv-
plot’’ package (http://www.cbs.dtu.dk/*eklund/survplot/)
in R.
Computation of risk category using the ‘‘strongest
genes’’
Using our validation database we identified the genes with
the strongest predictive power in all patients, in lymph
node positive, and in lymph node negative ER positive and
ER negative patients. First, a filtering was performed to
select only those probe sets which reliably work on the
microarray. Probe sets were retained having a median
expression over 890 (the whole-array median) or having a
median expression of at least 445 and covering at least 20%
of the gene and not mapping to multiple genes. After this,
the gene with the lowest p value and the highest HR value
in the given cohort of patients was selected. Then, the
second probe set was added, and the mean expression of
the two probe sets was used for classification. This was
repeated as long as the predictive power of the mean of the
used probe sets increased. A leave-one-out cross validation
(LOOCV) was performed in each of the three cohorts to
measure the robustness as whether the same genes will be
selected by excluding any of the samples. Finally, the
classification was implemented in RecurrenceOnline as the
‘‘Risk category using strongest genes’’ option.
Comparison of classification performance by using
ROC
Although we do not had access to the Oncotype DX scores
for the same samples, we contrasted area under the curve
(AUC) measures using our methods and published AUC
measures available for the Oncotype DX [29]. ROC
analysis was performed using MedCalc 11.6. (MedCalc
Software, Mariakerke, Belgium).
Results
Online system
We have established an online platform which enables the
computation of four different features using Affymetrix
HGU133A or HGU133plus2 microarray data. An example
of a complete analysis is depicted in Fig. 2b.
On these microarrays, some genes are measured by sev-
eral probe sets. For the analysis of ERBB2 status and ER
status, we used the probe sets with the highest average
expression. For the prediction of the recurrence score, one
can decide how to handle these probe sets for each gene. The
‘‘Average’’ computes the average expression of all available
probe sets for each gene. The ‘‘Best probe set’’ uses only the
best probe as measured by average expression of each probe
set and mapping to the gene by blasting to Ensembl genes.
Finally, as one of the housekeeping genes is related to pro-
liferation (GAPDH) [30], this gene can be excluded from the
analysis using the ‘‘Best probe-GAPDH’’ option.
The ER and ERBB2 status are computed using the
MAS5 normalized expression values. The computation of
the recurrence score is preceded by a transformation of the
linear MAS5 expression values to logarithmic scale. In
contrast to RT-PCR, where larger values mean lower
expression, larger values mean higher expression on
microarrays. Therefore, an inversion is necessary, and the
range top parameter defines in this context the top of the
dynamic range on the microarray.
Validation cohort
All together 2,472 microarray measurements were entered
into the validation database. The average relapse-free survival
is 6.39 ± 4.0 years with 869/2,239 relapses. Only lymph
node negative patients with available relapse-free survival
times (n = 1,509) were included in the basic classification
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using the recurrence score algorithm. The classification
resulted in 46% (n = 701) of patients classified into the low,
19% (n = 279) into the intermediate and 35% (n = 527) into
the high-risk group, the Kaplan–Meier plots for all three
categories are depicted in Fig. 3a. In these patients, the
difference in the survival curves were significant (P = 5.6E-
16, Hazard Ratio = 0.40, Confidence Interval = 0.32–0.50).
The significance was slightly reduced when only ER positive
samples were included for the recurrence score (P = 2.1E-
15, HR = 0.36, CI = 0.28–0.47 (see Fig. 3b). The classifi-
cation of the 1,509 lymph node negative patients using the
available clinical variables resulted in much lower signifi-
cances (ER status: P = 0.0002, HR = 0.66, CI = 0.51–0.86,
grade: P = not significant). In many previous publications,
authors reported not only the overall significance, but also the
significance between the worst and the best performing
Fig. 3 Kaplan–Meier plots of survival based on classification using
the recurrence score in all lymph node negative patients (n = 1,509)
(a), and in lymph node negative estrogen receptor positive patients
(b, n = 1,028, ER status is IHC based). The recurrence-
score-classification is also effective in only tamoxifen treated
(d, n = 251) estrogen receptor positive, lymph node negative
patients. Classification using the mean expression of the six
independent strongest genes in all patients regardless of lymph node
and ER status (d, n = 2,316), the strongest four genes in lymph node
negative ER positive patients (e, n = 1,077, ER status is array-based);
and the strongest three genes in lymph node positive patients
(f, n = 482)
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groups. Therefore, in a similar setting, we excluded the
median 10% of the samples from the analysis of the lymph
node negative, estrogen receptor positive samples (n = 1,077
remaining after reduction). In this setting, the recurrence
score yielded a slightly higher discriminative power
(P = 2.1E-15, HR = 0.34, CI = 0.26–0.45) (graph not
shown).
In an additional analysis option, we assessed only those
patients whose treatment protocols were published. The
survival plot showing the discriminative power in only
tamoxifen-treated patients (n = 251) is depicted in Fig. 3c.
Classification was not significant in lymph node positive
(n = 482) and in lymph node negative estrogen receptor
negative patients (n = 199).
Computation of risk category using the strongest genes
Using our validation database we selected the most informa-
tive genes with the highest predictive value in all patients with
available relapse-free survival time, in lymph node positive
patients, and in lymph node negative ER positive patients. Due
to the low number of patients in the lymph node negative ER
negative group (n = 199), we have not derived a discrimi-
native signature for these patients. In ‘‘all patients’’, the genes
CCT2, H2AFZ, RACGAP1, CCNB1, PGK1, and CCT6A are
used (n = 2316, classification power using the mean
expression of 2,600: P \ 1E-16, HR = 2.9, CI = 2.5–3.3,
see Fig. 3d). In ‘‘lymph node negative ER positive patients’’,
the mean expression of the genes MELK, CDC2, TOP2A, and
PRC1 are used (cutoff = 600, n = 1077, P \ 1E-16,
HR = 2.8, CI = 2.2–3.5, see Fig. 3e). In ‘‘lymph node
positive patients’’ the genes GARS, TCP1, and SQLE are used
for classification (n = 482; cutoff = 2600, P = 3.2E-9,
HR = 2.5, CI = 1.8–3.4, see Fig. 3f).
In the leave-one-out cross validation of the cohort
containing ‘‘all patients’’, and of the ‘‘lymph node negative
ER positive patients’’ the set of the top genes was con-
firmed in 100% of the analyses. In the ‘‘lymph node
positive’’ cohort, the selected genes were confirmed in
91.9% of the analyses. One gene, GATAD2A, surpassed
SQLE in 8.1% of the LOOCV tests. However, addition of
GATAD2A did not increase predictive power (P = 1E-8,
HR = 2.4, CI = 1.8–3.3.).
Validation of ER-status determination
Estrogen receptor status based on immunohistochemical
assessment (IHC) was available for 1,894 patients. Of
these, 267 were classified as negative and 1,438 as positive
by both IHC and microarray. Positive IHC with negative
microarray results were obtained in 35 samples and posi-
tive microarray with negative IHC results in 152 patients.
In summary, 88.5% of ER- and 90.5% of ER? samples
were classified correctly (see Fig. 4).
Another important feature of the ER status is the fact, that
only ER positive patients are eligible for the original recur-
rence score analysis. Therefore, we used our ER-status
determination and computed the recurrence score separately
(in lymph node negative patients with available survival) for
patients having positive IHC results (n = 1,028) and for
patients having positive microarray results (n = 1,090).
While the Kaplan–Meier survival plots delivered a significant
difference in both cases, the group having the array-based
ER-status determination had a stronger predictive power
Fig. 4 Validation of the estrogen receptor status determination in
1,894 patients with available immunhistochemistry results. The
patients are ordered on the basis of the expression of the probe set
205225_at, which corresponds to the ESR1 gene. The horizontal axis
crosses the vertical axis at 500, which is used as a threshold for
determining the estrogen receptor state as positive or negative. By
using this threshold, over 90% of patients are correctly classified
Breast Cancer Res Treat (2012) 132:1025–1034 1031
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(P = 2.1E-15, HR = 0.36, CI = 0.28–0.47 vs. P \ 1E-
16, HR = 0.36, CI = 0.28–0.46).
Comparison of classification performances
The AUC for the mean of strongest genes in all patients
was 0.695 (sensitivity = 63%, specificity = 67%). For the
strongest genes in the lymph node negative ER positive
patients the AUC was 0.613 (sensitivity = 67%, specific-
ity = 56%), and for the mean of the strongest genes of
lymph node positive patients the AUC was 0.569 (sensi-
tivity = 45%, specificity = 69%).
The AUC of RecurrenceOnline in the ROC analysis
using the 21-gene score for all lymph node negative and
ER positive patients was 0.637 (sensitivity = 61%, speci-
ficity = 62%). The previous AUC for Oncotype DX was
0.59 (sensitivity = 68%, specificity = 50%) [29].
The AUC for the estrogen status determination in the
ROC analysis was 0.807 (sensitivity = 97%, specific-
ity = 64%). The ROC plots are depicted on Fig. 5.
Array quality control
All together 77 samples (out of 2,472) failed at least one of
the quality control thresholds, 7 samples failed more than
one quality parameter. Of the first, 46 were lymph node
negative and of these, 39 were ER positive. Discrimination
of these patients by Kaplan–Meier survival analysis using
the computed RS score was impossible (P = 0.11).
Discussion
In our study, we aimed to prepare a tool capable to perform
different assays simultaneously by the use of genome-wide
microarrays. The approach is based on the fact that
microarray facilities are available at virtually all university
research centers. Thus, the microarray profiles of individ-
ual tumor specimens obtained at these centers can be
compared to and evaluated in the context of a large number
of clinical cases, which have been carefully characterized
in previous publications and, hence, can be considered as a
global reference. This can be performed in a shared
resource setting by www.recurrenceonline.com.
We successfully validated recurrenceonline.com using
2,472 independent gene expression profiles of breast cancer
specimens, available in GEO with clinical follow-up. The
predictive power of our study is higher as compared to the
original classifications [1]. Most probably there are several
reasons for this improvement: RNA is prepared from fresh
material prior to microarray analysis. This procedure
allows improves expression measurements compared to
paraffin embedded tissue as the source of RNA. The second
reason is the use of multiple probe sets for the measure-
ment of the genes on the microarrays. This enables us to
select the best probe sets which in turn will enable higher
prediction accuracy. Finally, we used a much larger set of
patients for validation than previous studies in combina-
tion. Unfortunately, direct comparison of recurrence online
with Oncotype Dx using tumour samples was not possible
as we do not had access to samples for which both Onc-
otype Dx assay and Affymetrix microarrays have been
performed.
We also show the capability to classify the patients
regardless of lymph node and ER status into high-risk and
low-risk cohorts using three independent sets of predictive
genes. As today all lymph node positive patients routinely
receive chemotherapy, a more in-depth analysis of these
patients will be needed for estimation of treatment
consequences.
The determination of ER status relies on a study of Gong
et al [27], who effectively used microarrays for ER and
HER2 receptor status determination. We implemented their
system, but had only enough data to validate the ER-status
prediction. The prediction achieved a very high success
rate of *90%. In addition, the measurement of the ER
status by microarray further improved the recurrence score
designed only for ER positive patients. For the HER2
determination, we also implemented a cut-off value based
on the expected bimodal distribution of the receptor
expression values as published by Li et al [28].
One might consider quality issues related to the use of
microarrays for the measurement of gene expression.
Reproducibility of the gene expression measurements was
Fig. 5 ROC plots for the implemented risk category prediction sets:
the array-based ER status determination vs. IHC based actual ER
status (1), the predictive power of the strongest genes identified in
all patients (2), LN-ER? patients (3), LN? patients (4) and the
predictive power of the recurrence-online computed recurrence
score (5)
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already confirmed by the MAQC consortia [31]. However,
the high data volume and data complexity in microarray
experiments carry many potential sources of unwanted
variation that could compromise the results if left uncon-
trolled. This growing concern and awareness of the
importance of assessing the quality of generated micro-
array data was assessed in a review published by Heber and
Sick [24]. Therefore, we implemented a quality metrics
measurement based on their suggested parameters. Partic-
ularly, seven different quality parameters related to biases
in sample processing, hybridization and scanning are
assessed by www.recurrenceonline.com. The value of this
added analysis is outlined by the fact, that the classification
of the samples with failed quality control was not suc-
cessful. We have set up the system to leave the decision to
the investigator, and the report gives a warning in case that
the quality of the microarray used is low.
Besides the validation of proprietary analysis pipelines,
our system can accelerate prognosis prediction by enabling
rapid evaluation of locally processed samples. Theoreti-
cally, the local diagnostic pathway can be completed in
*24 h, thereby reducing the time currently needed for
such an analysis by over 95%. The computational analysis
itself is completed in less than 10 min. The speed could
bring additional benefits for the patients, who could receive
the most appropriate treatment within a shorter time.
In summary, we developed an online classification
system capable of using common genome-wide micro-
arrays to assess hormone receptor status and to compute the
risk of recurrence. The system performs all bioinformatic
steps automatically and is therefore also suitable for users
with negligible statistical knowledge. As the present
scheme can be extended with additional gene sets and be
applied to other cancer types, one might envision a future
single step approach, which permits diagnosis of different
tumor types in the same automated pipeline.
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